Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.77B |
| 2 |
McKesson
MCK
|
+$2.38B |
| 3 |
SpaceX
SPCX
|
+$2.3B |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$2.05B |
| 5 |
Amazon
AMZN
|
+$1.37B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.96B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$3.11B |
| 3 |
Honeywell
HON
|
+$1.96B |
| 4 |
Salesforce
CRM
|
+$1.47B |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$775M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.02% |
| 2 | Technology | 24.63% |
| 3 | Financials | 9.78% |
| 4 | Healthcare | 7.32% |
| 5 | Industrials | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
6876
DELISTED
First Seacoast Bancorp
FSEA
| $10.1K | ﹤0.01% |
+600
| New | +$8.99K |
2026 Q2
0 quarters
|
|
6877
Gelteq Ltd
GELS
$5.25M
| $10.1K | ﹤0.01% |
+15,000
| New | +$9.63K |
2026 Q2
0 quarters
|
|
6878
Harvard Bioscience
HBIO
$37.5M
| $10K | ﹤0.01% |
1,627
-1
| -0.1% | -$6 |
2013 Q2
52 quarters
|
|
6879
Rocket One Inc
RKTO
$14.9M
| $10K | ﹤0.01% |
10,006
| – | – |
2022 Q4
14 quarters
|
|
6880
Pearl Diver Credit Co
PDCC
$56.2M
| $9.96K | ﹤0.01% |
1,000
| – | – |
2025 Q3
3 quarters
|
|
6881
VanEck Emerging Markets Bond ETF
EMBX
$263M
| $9.95K | ﹤0.01% |
194
-227
| -54% | -$11.7K |
2025 Q4
2 quarters
|
|
6882
T-Rex 2X Long Alphabet Daily Target ETF
GOOX
$65.6M
| $9.81K | ﹤0.01% |
122
+77
| +171% | +$6.53K |
2025 Q4
2 quarters
|
|
6883
Mega Fortune Co
MGRT
| $9.76K | ﹤0.01% |
134
-125
| -48% | -$11.9K |
2026 Q1
1 quarter
|
|
6884
iShares World ex U.S. Carbon Transition Readiness Aware Active ETF
LCTD
$315M
| $9.63K | ﹤0.01% |
167
-169
| -50% | -$9.78K |
2024 Q3
7 quarters
|
|
6885
SkyAI Inc
SKYA
$112M
| $9.6K | ﹤0.01% |
8,649
| – | – |
2025 Q1
5 quarters
|
|
6886
AdvisorShares Psychedelics ETF
PSIL
$45.8M
| $9.6K | ﹤0.01% |
399
+149
| +60% | +$2.98K |
2021 Q4
18 quarters
|
|
6887
IGC Pharma
IGC
$28.5M
| $9.57K | ﹤0.01% |
35,198
+80
| +0.2% | +$24 |
2019 Q1
29 quarters
|
|
6888
iShares Yield Optimized Bond ETF
BYLD
$417M
| $9.56K | ﹤0.01% |
422
-1,303
| -76% | -$29.5K |
2023 Q1
13 quarters
|
|
6889
McElhenny Sheffield Managed Risk ETF
MSMR
$183M
| $9.5K | ﹤0.01% |
270
| – | – |
2025 Q3
3 quarters
|
|
6890
Donegal Group Class B
DGICB
$645M
| $9.38K | ﹤0.01% |
430
| – | – |
2024 Q4
6 quarters
|
|
6891
Educational Development Corp
EDUC
$11.1M
| $9.32K | ﹤0.01% |
6,171
| – | – |
2013 Q4
50 quarters
|
|
6892
Acrivon Therapeutics
ACRV
$81.4M
| $9.31K | ﹤0.01% |
5,233
-31,438
| -86% | -$53.4K |
2022 Q4
14 quarters
|
|
6893
BioHarvest Sciences
BHST
$36.7M
| $9.29K | ﹤0.01% |
3,250
| – | – |
2025 Q1
5 quarters
|
|
6894
Frontier Asset Global Small Cap Equity ETF
FGSM
$46.9M
| $9.27K | ﹤0.01% |
+266
| New | +$8.99K |
2026 Q2
0 quarters
|
|
6895
Oxbridge Re Holdings
OXBR
$7.62M
| $9.27K | ﹤0.01% |
9,000
| – | – |
2025 Q3
3 quarters
|
|
6896
American Shared Hospital Services
AMS
$8.45M
| $9.26K | ﹤0.01% |
5,858
| – | – |
2014 Q4
46 quarters
|
|
|
MVO
6897
DELISTED
MV Oil Trust
MVO
| $9.25K | ﹤0.01% |
5,225
+4,225
| +423% | +$8.81K |
2013 Q4
50 quarters
|
|
6898
Fundrise Innovation Fund
VCX
$914M
| $9.25K | ﹤0.01% |
107
+7
| +7% | +$1K |
2026 Q1
1 quarter
|
|
6899
CitroTech Inc
CITR
| $9.24K | ﹤0.01% |
1,674
+477
| +40% | +$3.38K |
2026 Q1
1 quarter
|
|
6900
Valaris Ltd Warrants
VAL.WS
$675M
| $9.21K | ﹤0.01% |
1,099
-58
| -5% | -$910 |
2021 Q2
20 quarters
|
|
Similar funds
Morgan Stanley's Q2 2026 Portfolio in Review
As of Q2 2026, Morgan Stanley held 8,715 positions worth $1.89T, up 14% from $1.66T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Morgan Stanley's Q2 2026 filing shows 425 new, 3,807 increased, 3,215 reduced and 303 closed positions. Its largest new stake was SpaceX: 13,532,773 shares worth $2.31B. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.96B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q2 2026 buy was SpaceX: 13,532,773 shares worth $2.31B.
- Morgan Stanley added most to NVIDIA in Q2 2026, an estimated $2.77B increase.
- Morgan Stanley's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.96B.
- Morgan Stanley fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $404M.
- Morgan Stanley's ten largest holdings make up 21% of its $1.89T portfolio in Q2 2026.
- Morgan Stanley opened 425 new positions and closed 303 in Q2 2026.
- Morgan Stanley's portfolio value rose 14% quarter-over-quarter to $1.89T.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.